PARP inhibition and synthetic lethality in ovarian cancer

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43
   PubMed Web of Science ®Google Scholar
• Hurt J, Richardson D, Seamon L, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009;115:396-400
   PubMed Web of Science ®Google Scholar
• Eskander RN, Cripe J, Bristow RE. Intraperitoneal Chemotherapy from Armstrong to HIPEC: Challenges and Promise. Curr Treat Options Oncol 2014;15:27-40
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
   PubMed Web of Science ®Google Scholar
• Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2001;2:446-57
   PubMed Web of Science ®Google Scholar
• Grompe M, D’Andrea A. Fanconi anemia and DNA repair. Hum Mol Genet 2001;10:2253-9
   PubMed Web of Science ®Google Scholar
• D’Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34
   PubMed Web of Science ®Google Scholar
• Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001;7:249-62
   PubMed Web of Science ®Google Scholar
• Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9
   PubMed Web of Science ®Google Scholar
• Pothuri B. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Ann Oncol 2013;24(Suppl 8):viii22-7
   PubMedGoogle Scholar
• Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82
   PubMed Web of Science ®Google Scholar
• Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247-54
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999;4:511-18
   PubMed Web of Science ®Google Scholar
• Tutt A, Bertwistle D, Valentine J, et al. Mutation in BRCA2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001;20:4704-16
   PubMed Web of Science ®Google Scholar
• Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-5
   PubMed Web of Science ®Google Scholar
• Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306:1557-65
   PubMed Web of Science ®Google Scholar
• Tan DS, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008;26:5530-6
   PubMed Web of Science ®Google Scholar
• Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008;26:20-5
   Google Scholar
• Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95
   PubMed Web of Science ®Google Scholar
• McLaughlin JR, Rosen B, Moody J, et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2013;105:141-8
   Google Scholar
• Hyman DM, Zhou Q, Iasonos A, et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2012;118:3703-9
   PubMed Web of Science ®Google Scholar
• Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012;307:382-90
   PubMed Web of Science ®Google Scholar
• Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res 2010;16:4527-31
   PubMed Web of Science ®Google Scholar
• Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006;25:5864-74
   PubMed Web of Science ®Google Scholar
• Poirier GG, de Murcia G, Jongstra-Bilen J, et al. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc Natl Acad Sci USA 1982;79:3423-7
   PubMed Web of Science ®Google Scholar
• Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74
   PubMed Web of Science ®Google Scholar
• Dantzer F, de La Rubia G, Menissier-De Murcia J, et al. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 2000;39:7559-69
   PubMed Web of Science ®Google Scholar
• Schultz N, Lopez E, Saleh-Gohari N, Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 2003;31:4959-64
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3
   PubMed Web of Science ®Google Scholar
• McCabe N, Lord CJ, Tutt AN, et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005;4:934-6
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-17
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013;14:882-92
   PubMed Web of Science ®Google Scholar
• Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014;25:32-40
   PubMed Web of Science ®Google Scholar
• Turner N, Tutt A, Ashworth A. Hallmarks of ’BRCAness’ in sporadic cancers. Nat Rev Cancer 2004;4:814-19
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23
   PubMed Web of Science ®Google Scholar
• Vencken PM, Kriege M, Hoogwerf D, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011;22:1346-52
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28:3555-61
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30:372-9
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patient with platinum sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (MRCAm). J Clin Oncol 2013;31:Abstract 5505
   Web of Science ®Google Scholar
• Coleman RL Sill M, Aghajanian C, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation. Gyn Oncol 2014;Abstract 136
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01844986
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01874353
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01847274
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01891344
   Google Scholar
• Lee SA, Roques C, Magwood AC, et al. Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression. DNA Repair (Amst) 2009;8:170-81
   PubMed Web of Science ®Google Scholar
• Bonner WM, Redon CE, Dickey JS, et al. GammaH2AX and cancer. Nat Rev Cancer 2008;8:957-67
   PubMed Web of Science ®Google Scholar
• Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012;106:468-74
   PubMed Web of Science ®Google Scholar
• Saijo N. Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat 2012;44(1):1-10
   PubMed Web of Science ®Google Scholar